Primary pancreatic lymphoma: diagnostic and therapeutic dilemma

Pancreas. 2006 Aug;33(2):192-4. doi: 10.1097/01.mpa.0000227910.63579.15.

Abstract

Objectives: Non-Hodgkin lymphoma predominantly involving the pancreas is a rare tumor and accounts for less than 0.7% of all pancreatic malignancies and 1% of extranodal lymphomas. Diagnosis of primary pancreatic lymphoma can be difficult because it may mimic carcinoma. The principal aims of this review were to highlight the difficulties encountered in making a diagnosis and to identify the role of surgery.

Methods: A PubMed search was conducted using the following terms: primary pancreatic lymphoma and non-Hodgkin lymphoma of the pancreas. Additional references were sourced from key articles.

Results: A total of 89 reported cases of pancreatic lymphoma between 1951 and 2005 were reviewed. An accurate preoperative diagnosis of primary pancreatic lymphoma is not always possible. A complete response rate of 100% and a long-term survival rate of 94% have been reported with surgery and adjuvant chemotherapy when compared with a 5-year survival rate of less than 50% and an overall 3-year disease-free survival rate of 44% with current chemotherapy, radiotherapy, or combined methods.

Conclusion: Pancreaticoduodenectomy may have a therapeutic role in association with chemotherapy.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Humans
  • Lymphoma, B-Cell / diagnostic imaging
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / surgery*
  • Lymphoma, Non-Hodgkin / diagnostic imaging
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / surgery*
  • Male
  • Middle Aged
  • Pancreatectomy*
  • Pancreatic Neoplasms / diagnostic imaging
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / surgery*
  • Tomography, X-Ray Computed
  • Ultrasonography

Substances

  • Antineoplastic Agents